Cancer Res Treat.  2016 Jan;48(1):266-272. 10.4143/crt.2014.206.

A Clinicopathological Review of Pulmonary Metastasis from Uterine Cervical Cancer

• Ki EY
• Lee KH
• Park JS
• Hur SY

• KMID: 2152284
• DOI: http://doi.org/10.4143/crt.2014.206

Abstract

PURPOSE
The purpose of this study was to investigate the clinicopathological features of pulmonary metastasis from cervical cancer.
MATERIALS AND METHODS
We reviewed the medical records of 56 patients with cervical cancer who developed pulmonary metastasis after radical hysterectomy, postoperative concurrent chemoradiation or systemic chemotherapy between January 1990 and March 2014.
RESULTS
Fifty-six patients were diagnosed with pulmonary metastasis from cervical cancer. The prevalence of pulmonary metastasis was 3.6%. The mean event-free duration was 12 months. Twelve patients underwent surgical removal of metastatic lesions. The overall survival (OS) of patients with < or = 3 metastatic lung lesions was 40.7 months, longer than those with > 4 lesions (25 months, p=0.034). The OS of patients who underwent surgical resection was 53.8 months, longer than that of those who did not (p=0.006). In addition, the OS of patients with adjuvant platinum-based chemotherapy was 32.6 months (p=0.027).
CONCLUSION
In this study, we found that the number of metastatic nodules, surgical resection, and postoperative platinum-based chemotherapy can influence clinical outcome. Further studies on prognostic factors and successful treatment modalities are warranted.

Keyword

Uterine cervical neoplasms; Pulmonary metastasis; Prognosis

MeSH Terms

Drug Therapy
Humans
Hysterectomy
Lung
Medical Records
Neoplasm Metastasis*
Prevalence
Prognosis
Uterine Cervical Neoplasms*

Figure

• 

  Fig. 1. Overall survival decreases by the initial stage in pulmonary metastasis (p=0.001, the log-rank test).

• 

  Fig. 2. Overall survival by the histologic type. There is no significant difference between squamous cell and non-squamous cell type (log-rank test, p=0.2).

• 

  Fig. 3. The relationship between event-free duration (EFD) and overall survival. Overall survival becomes longer with increasing EFD. Overall survival increases abruptly after EFD reaches 24 months (p=0.019).

• 

  Fig. 4. Overall survival by resectability. The resection group has better overall survival than the non-resection group (log-rank test, p=0.025).

Reference

References

1. Yamamoto K, Yoshikawa H, Shiromizu K, Saito T, Kuzuya K, Tsunematsu R, et al. Pulmonary metastasectomy for uterine cervical cancer: a multivariate analysis. Ann Thorac Surg. 2004; 77:1179–82.

2. Barter JF, Soong SJ, Hatch KD, Orr JW, Shingleton HM. Diagnosis and treatment of pulmonary metastases from cervical carcinoma. Gynecol Oncol. 1990; 38:347–51.

3. Plaza JA, Ramirez NC, Nuovo GJ. Utility of HPV analysis for evaluation of possible metastatic disease in women with cervical cancer. Int J Gynecol Pathol. 2004; 23:7–12.

4. Wang CW, Wu TI, Yu CT, Wu YC, Teng YH, Chin SY, et al. Usefulness of p16 for differentiating primary pulmonary squamous cell carcinoma from cervical squamous cell carcinoma metastatic to the lung. Am J Clin Pathol. 2009; 131:715–22.

5. Ge J, Gou HF, Chen Y, Cheng K, Li LH, Dong H, et al. Clinical characteristics of patients with solitary pulmonary mass after radical treatment for primary cancers: pulmonary metastasis or second primary lung cancer? Cancer Invest. 2013; 31:397–403.

6. Imachi M, Tsukamoto N, Matsuyama T, Nakano H. Pulmonary metastasis from carcinoma of the uterine cervix. Gynecol Oncol. 1989; 33:189–92.

7. Anderson TM, McMahon JJ, Nwogu CE, Pombo MW, Urschel JD, Driscoll DL, et al. Pulmonary resection in metastatic uterine and cervical malignancies. Gynecol Oncol. 2001; 83:472–6.

8. Carlson V, Delclos L, Fletcher GH. Distant metastases in squamous-cell carcinoma of the uterine cervix. Radiology. 1967; 88:961–6.

9. Ito H, Shigematsu N, Kawada T, Kubo A, Isobe K, Hara R, et al. Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy. Gynecol Oncol. 1997; 67:154–61.

10. Krebs HB, Helmkamp BF, Sevin BU, Poliakoff SR, Nadji M, Averette HE. Recurrent cancer of the cervix following radical hysterectomy and pelvic node dissection. Obstet Gynecol. 1982; 59:422–7.

11. Shiromizu K, Kasamatsu T, Takahashi M, Kikuchi A, Yoshinari T, Matsuzawa M. A clinicopathological study of postoperative pulmonary metastasis of uterine cervical carcinomas. J Obstet Gynaecol Res. 1999; 25:245–9.

12. Rose PG, Baker S, Fournier L, Nelson BE, Hunter RE. Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence. Am J Obstet Gynecol. 1993; 168:942–6.

13. Ngan HY, Cheng GT, Cheng D, Wong LC, Ma HK. Posttreatment serial serum squamous cell carcinoma antigen (SCC) in the monitoring of squamous cell carcinoma of the cervix. Int J Gynecol Cancer. 1996; 6:115–9.

14. Anraku M, Yokoi K, Nakagawa K, Fujisawa T, Nakajima J, Akiyama H, et al. Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. J Thorac Cardiovasc Surg. 2004; 127:1107–12.

15. Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113:37–49.

16. Fuller AF Jr, Scannell JG, Wilkins EW Jr. Pulmonary resection for metastases from gynecologic cancers: Massachusetts General Hospital experience, 1943-1982. Gynecol Oncol. 1985; 22:174–80.

17. Downey RJ. Surgical treatment of pulmonary metastases. Surg Oncol Clin N Am. 1999; 8:341.

18. Seki M, Nakagawa K, Tsuchiya S, Matsubara T, Kinoshita I, Weng SY, et al. Surgical treatment of pulmonary metastases from uterine cervical cancer: operation method by lung tumor size. J Thorac Cardiovasc Surg. 1992; 104:876–81.

19. Girard P, Baldeyrou P, Le Chevalier T, Lemoine G, Tremblay C, Spielmann M, et al. Surgical resection of pulmonary metastases. Up to what number? Am J Respir Crit Care Med. 1994; 149:469–76.

20. Alberts DS, Martimbeau PW, Surwit EA, Oishi N. MitomycinC, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix. Cancer Clin Trials. 1981; 4:313–6.

21. Wallace HJ Jr, Hreshchyshyn MM, Wilbanks GD, Boronow RC, Fowler WC Jr, Blessing JA. Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep. 1978; 62:1435–41.